Overview
The purpose of this study is to evaluate connectivity of the FDA approved DexCom G7® continuous glucose monitor in the operating room. Continuous glucose monitors are applied to the skin and a thin sampling filament is inserted into the skin and measures blood sugar in the interstitial fluid. The DexCom G7® is used regularly outside of the operating room to monitor blood sugar, however the use of the device in the operating room environment has been limited by connectivity issues. This study will assess device connectivity at different monitoring sites.
Description
This feasibility pilot study will assess connectivity of the DexCom G7® continuous glucose monitoring device (CGM) in the operating room environment at different locations on the body. The investigators believe device connectivity is affected by use of electrocautery. The monitoring sites were selected to limit electromagnetic interference from electrocautery.
One cohort will have the CGM device placed on the deltoid and the electrodispersive pad placed on the thigh and the other cohort will have the CGM device placed on the thigh with the electrodispersive pad on the opposite thigh.
Study personnel will note when electrocautery is used throughout the surgery and observe if the DexCom G7® continues to maintain connectivity with the receiver and provides a glucose reading. Comparing the timing of electrocautery use with connectivity to the DexCom G7® receiver provides important insight to the relationship between electrocautery and device connectivity.
The CGM readings will solely be used for feasibility purposes for this study and not for determining interventions for the subjects.
Eligibility
Inclusion Criteria:
- Adults age 18 and above able to consent for themselves
- Willingness and ability to participate in study procedures
- Surgery length estimated 3 hours or longer
Exclusion Criteria:
- Cardiothoracic surgical patients
- Plan for intraoperative radiologic imaging
- Patients on IV infusion of insulin prior to surgery
- Anemia with hemoglobin less than 7
- Patients on hydroxyurea
- Patients with known adhesive allergies
- Pregnant women